羊角天麻中的两个新倍半萜

羊角天麻中的两个新倍半萜刘绍华,程菊英（广西植物研究所,桂林５４１００６）吴大刚（中国科学院昆明植物研究所植物化学开放实验室,昆明６５０２０４）关键词羊角天麻;倍半萜;羊角天麻素Ⅰ;羊角天麻素ⅡＴＷＯＮＥＷＳＥＳＱＵＩＴＥＲＰＥＮＥＳＦＲＯＭＤＯＢＩ...     

Regulatory properties of rabbit red blood cell hexokinase at conditions close to physiological

The true level of hexokinase in rabbit erythrocytes was determined by three different methods, including the spectrophotometric glucose-6-phosphate dehydrogenase coupled assay and a new radioisotopic assay. The value found at 37°C (pH 7.2) was 10.23±1.90 μmol/h per ml red blood cells, which is lower than previously reported values. More than 40 cellular components of the rabbit erythrocytes were tested for their effects on the enzyme. Their intracellular concentrations were also determined. Several of these compounds were found to be competitive inhibitors of the enzyme with respect to Mg·ATP^2?. Furthermore, reduced glutathione at a concentration of 1 mM was able to maintain hexokinase in the reduced state with full catalytic activity. The ability of orthophosphate to remove the inhibition of some phosphorylated compounds was examined under conditions similar to cellular (pH 7.2 and 50 μM of orthophosphate) and found to be of no practical interest. In contrast, the binding of ATP^4? and 2,3-diphosphoglycerate to the rabbit hemoglobin significantly modifies their intracellular concentrations and the formation of the respective Mg complexes. The pH-dependence of the reaction velocity and of the kinetic properties of the enzyme in different buffer systems were also considered. This information was computerized, and the rate of glucose phosphorylation in the presence of the mentioned compounds was determined. The value obtained, 1.94±0.02 μmol/h per ml red blood cells, is practically identical to the measured rate of glucose utilization by intact rabbit erythrocytes (1.92±0.3 μmol/h per ml red blood cells). These results provide further evidence for the central role of hexokinase in the regulation of red blood cell glycolysis.     

Hexokinase isoenzymes in diabetes

Hexokinase is present in the tissues in four isoenzymic forms. Cerebral tissue contains predominantly Type I hexokinase which is believed to be insulin-insensitive. In cerebral tissue about 60 to 70% of the hexokinase is bound to the particulate fraction. The changes in the distribution of hexokinase Type I and Type II together with the bound and free hexokinase have been studied in control, diabetic and diabetic animals treated with insulin. The results indicate that the presence of insulin is essential for the normal binding of the hexokinase to the particulate fraction. In heart tissue, Type II hexokinase bound to the pellet shows a significant decrease in diabetes, which is reversed on insulin administration.     

Hexokinase Levels in Discrete Regions of Rat Brain: Evaluation by Quantitative Immuno fluoresence Using Interactive Laser Cytometry and Comparison with Basal Rates of Glucose Utilization

Relative levels of hexokinase (ATP:D-hexose 6-phosphotransferase, EC 2.7.1.1) have been determined in 16 discrete regions of adult rat brain by a quantitative immunofluorescence method. The distribution of immunofluorescence in brain sections was determined by interactive laser cytometry and related to hexokinase content by comparison with standard sections containing known amounts of the enzyme. In many of these regions, referred to here as group I regions, hexokinase content was correlated with previously reported basal rates of glucose utilization. However, several regions (group II regions) in which hexokinase content exceeded that expected from basal rates of glucose utilization were also detected. Compared with the corresponding regions from albino rat brain, higher hexokinase levels were found in the dorsal and ventral lateral geniculate (group I regions) of pigmented Norway rats, a result reflecting previously reported increased glucose utilization by these regions in pigmented rats. There was no difference in hexokinase levels in the superior colliculus, a group II structure, from albino and pigmented rats, a finding implying that a reported increase in rate of glucose utilization in the superior colliculus of pigmented rats is effected without an increase in hexokinase content. It is suggested that group II regions may be adapted to sustain increases in rates of glucose utilization that are, relative to basal rates, considerably greater than those experienced by group I regions.     

我国大豆种子中球蛋白2S组分的分离纯化及部分性质的研究

根据大豆种子球蛋白和清蛋白溶解性不同的原理,分离出我国红丰3号大豆种子球蛋白2S粗制剂,再用SephadexG-100柱层析对其进行纯化。纯化后的球蛋白表现SDS-聚丙烯酰胺凝胶电泳非均一性。对这样纯化过的2s球蛋白进行DEAE-纤维素离子交换柱层析分离,用0.1—0.5mol/L pH7.6磷酸盐缓冲液进行线性梯度洗脱,得到四个洗脱峰,每个峰都获得了PAGE单一条带。四个组分分别命名为SⅡP_1,SⅡP_2,SⅡP_3和SⅡP_4。然后对这四种蛋白质的某些性质进行了研究,结果表明四者的分子量按以上顺序分别为22800,21500,19200和17800。所含残基数分别为191,179,163和147个。SⅡP_1,SⅡP_2和SⅡP_3三者的沉降系数(S_(20),w)分别为2.1S,1.9S和1.8S。N-末端分析表明这四种蛋白质的N-末端均为天门冬氨酸.还发现SⅡP_2具有能抑制α-胰凝乳蛋白酶的活性。本实验所提纯的这个抑制剂的一个ATEE(N-乙酰-L-酪氨酸乙酯)单位为0.4μg抑制剂蛋白(仅指对α-chymotrypsin发生作用)。α-chymotrypsin与此抑制剂相互作用时的摩尔数比初步判断为E/I=2/1。     

云南松形态和叶片碳氮磷化学计量及其海拔变化特征

云南松(Pinus yunnanensis Franch.)是我国西南地区特有的物种,在当地的经济、生态和水土保持功能方面占有重要地位。本研究以云南东北部不同海拔的云南松天然次生林为对象,测定了成年植株的胸径、株高、叶片长度、干重、比叶长及叶片碳、氮、磷含量,分析了不同海拔下叶片碳氮磷化学计量特征。结果表明:随海拔升高,胸径、株高、叶P含量和叶C∶N呈现"中间高,两头低"的趋势,而叶C∶P和N∶P呈现的趋势与叶P和叶C∶N的相反;云南松叶片单束松针长、比叶长、叶C、N随海拔升高呈明显降低的趋势,而单束松针重呈增加的趋势;各海拔的N∶P值(平均值为5.82±0.10)均小于14,且与植株胸径、株高呈显著负相关;该地区云南松对海拔具有较强的适应性,植株生长主要受N元素的营养限制,该结果支持生长速率假说。本研究揭示了云南松化学计量特征的空间格局变化规律,为云南松林的经营管理提供科学依据。     

不同预后脓毒症患者血清降钙素原、C反应蛋白与凝血功能指标和APACHE Ⅱ评分的关系分析

目的:探讨不同预后脓毒症患者血清降钙素原(PCT)、C反应蛋白(CRP)与凝血功能指标和急性生理和慢性健康状况评分系统Ⅱ(APACHEⅡ)评分的关系。方法:回顾性分析2015年1月至2019年1月期间深圳市第二人民医院重症医学科收治的160例脓毒症患者(脓毒症组)与在深圳市第二人民医院接受住院治疗的160例非脓毒症患者(非脓毒症组)的临床资料,根据脓毒症组患者住院28d后的预后情况分为存活组118例和死亡组42例,比较脓毒症组和非脓毒症组以及死亡组和存活组患者血清PCT和CRP水平、APACHE II评分以及凝血功能指标,采用Pearson相关性回归分析脓毒症患者血清降钙素原和CRP水平与APACHEⅡ评分以及凝血功能指标相关性。结果:与非脓毒症组相比,脓毒症组的血清PCT和CRP水平以及APACHEⅡ评分明显升高,凝血酶原时间(PT)和部分凝血活酶时间(APTT)明显延长(均P<0.05)。与存活组相比,死亡组的血清PCT和CRP水平以及APACHEⅡ评分明显升高,而PT和APTT均明显延长(均P<0.05)。Pearson相关性回归分析结果显示,血清PCT和CRP水平与APACHEⅡ评分、PT及APTT均呈正相关(均P<0.05)。结论:脓毒症患者血清PCT和CRP水平异常升高,APACHEⅡ评分及凝血功能指标均与血清PCT和CRP水平呈正相关,检测血清PCT和CRP水平有助于评估脓毒症患者的预后。     

缬沙坦氢氯噻嗪对高血压合并心力衰竭患者Ang Ⅱ、NT-ProBNP及CTGF的作用分析

目的:探讨缬沙坦氢氯噻嗪对高血压合并心力衰竭患者血管紧张素Ⅱ(Ang Ⅱ)、氨基末端脑钠尿肽前体(NT-ProBNP)及结缔组织生长因子(CTGF)的作用。方法:选择2016年3月到2019年3月我院收治的高血压合并心力衰竭患者113例进行研究,以随机数表法分为观察组(n=57)和对照组(n=56)。对照组给予贝那普利治疗,观察组在对照组的基础上采用缬沙坦氢氯噻嗪治疗。比较两组患者的临床疗效、Ang Ⅱ、NT-ProBNP及CTGF、左心室射血分数(LVEF)、左心室收缩末期内径(LVESd)、左心室舒张末期内径(LVEDd)、收缩压(SBP)、舒张压(DBP)水平变化情况及并发症发生情况。结果:治疗后,两组总有效率分别为92.98%、73.21%,差异显著;治疗前,两组Ang Ⅱ、NT-ProBNP及CTGF水平无显著差异(P>0.05);治疗后,两组Ang Ⅱ、NT-ProBNP及CTGF水平均显著改善,且观察组均低于对照组(P<0.05);治疗前,两组心功能水平无显著差异(P>0.05);治疗后,两组心功能水平均显著改善,且观察组LVEF高于对照组,LVESd、LVEDd低于对照组(P<0.05);治疗前,两组血压水平无显著差异(P>0.05);治疗后,两组血压水平均显著改善,且观察组SBP、DBP水平显著低于对照组,差异显著(P<0.05);两组并发症总发生率分别为7.02%、10.71%,差异无显著差异(P>0.05)。结论:在高血压合并心力衰竭患者中应用缬沙坦氢氯噻嗪辅助治疗效果显著,可有效改善患者心功能、Ang Ⅱ、NT-ProBNP及CTGF水平。     

不依赖连接反应的高通量克隆方法

以脱脂菜籽粕酶解的复合氨基酸为主要原料,螯合率为考察指标,采用L16(4 5)正交试验设计,考察了pH值、温度、时间和配位比对螯合率的影响.结果显示,影响因素的高低顺序为:配位比＞pH值＞时间＞温度.结果表明,复合氨基酸与铜螯合的主要影响因素为pH值和配位比,且配位比的影响达到极显著水平.最佳工艺条件为:时间50 min,温度50℃,配位比2∶1,pH为9,此条件下的复合氨基酸螯合铜的螯合率为94.59％,氨基酸含量为30.2％.     

非人灵长类个性化麻醉方案的探讨

目的 比较氯胺酮、舒泰、速眠新Ⅱ、戊巴比妥钠等4种全身麻醉药或其组合对非人灵长类的麻醉效果,探寻能替代或者减少氯胺酮使用的个性化麻醉方案。方法 以单独使用氯胺酮麻醉的方案作为对照,另设单独使用舒泰、氯胺酮复合速眠新Ⅱ、舒泰复合速眠新Ⅱ和戊巴比妥钠复合速眠新Ⅱ等麻醉4个实验组,每组选取5只食蟹猴进行实验,记录麻醉后的心率、体温、血氧饱和度、以及麻醉诱导时间和维持时间,以比较各方案的麻醉效果。结果 与单独使用氯胺酮麻醉比较,其他四种麻醉方案在心率、体温、血氧饱和度和麻醉诱导时间上均无显著性差异,不同方案麻醉维持时间分布在30~200min之间。在非人灵长类的全身麻醉中,舒泰可以很好地替代氯胺酮;氯胺酮复合速眠新Ⅱ麻醉可取得较长的麻醉维持时间,并减少氯胺酮的使用量;舒泰与速眠新Ⅱ联用、戊巴比妥钠与速眠新Ⅱ联用的方案也可替代氯胺酮,且麻醉维持时间较长。结论 在一定的麻醉时间内,联合用药可以降低氯胺酮的使用量,不同麻醉方案灵活运用可满足不同实验对麻醉维持时间的需求。